G1 Therapeutics to Present at Investor Conferences in November 2018

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/2/2026

1. PANW
2. GTLB
3. DELL
4. MDB
5. GOOGL

6. VRTS
7. SPY
8. HPE
9. USO
10. SNOW

Get Alerts GTHX Hot Sheet

Price: $7.15 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will provide a company overview at the following upcoming investor conferences in November:

Cowen 2nd Annual I/O NEXT Summit: Friday, November 9 at 8:10 a.m. ET at the Marriott Marquis in Washington, DC.
Stifel 2018 Healthcare Conference: Tuesday, November 13 at 11:45 a.m. ET at the Lotte New York Palace Hotel in New York, NY.
Evercore/ISI HEALTHCONx: Tuesday, November 27 at 1:15 p.m. ET at the Boston Harbor Hotel in Boston, MA.
Piper Jaffray 19th Annual Health Care Conference: Wednesday, November 28 at 11 a.m. ET at the Palace Hotel in New York, NY.

To access the live webcast presentation for the Stifel 2018 Healthcare Conference, please visit the Events & Presentations page within the Investors section of the G1 website. Replays of the webcast will be archived on the same page for 30 days following the event.

About G1 TherapeuticsG1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs, trilaciclib, lerociclib and G1T48, that are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:Jeff MacdonaldHead of Investor Relations / Public Relations919-907-1944[email protected]